Option chain shows key data for Daiichi Sankyo Co's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Daiichi Sankyo Co.

Daiichi Sankyo Co (OTC:DSNKY) Stock, Option Chain

DAIICHI SANKYO

Daiichi Sankyo Co

Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2023, approximately one third of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates, or ADCs. Its three lead ADCs are Enhertu (HER2), Dato-DXd (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu entered the clinic in 2015 and received its first US approval in December 2019 for third-line late-stage HER2-positive breast cancer. It is also approved for HER2-positive stomach cancers and HER2 mutant non-small cell lung cancer.

astrazeneca

Biotech

Large Cap

News

Health Care

Movers

General

DSKYF

DSNKY

AstraZeneca&#39;s Imfinzi gains FDA Priority Review for bladder cancer. Key trial data shows improved survival and progression outcomes in treated patients.

After Lung Cancer Approval, AstraZeneca&#39;s Imfinzi Goes Under FDA Priority Review For Bladder Cancer

Shanghai,china-feb.12th,2023:,Astrazeneca,Company,Office,Building,And,Brand,Logo.

AstraZeneca released results from the TROPION-Breast01 Phase 3 trial of datopotamab deruxtecan, showing no statistically significant improvement in overall survival. The trial met its progression-free survival endpoint, with improved patient-reported outcomes and a consistent safety profile.

Latest Trial Setback For AstraZeneca&#39;s Dato-DXd, The Drug Fails To Extend Lives Of Pretreated Breast Cancer Patients

SMMT

Merck reported topline data from its HERTHENA-Lung02 phase 3 trial of patritumab deruxtecan in EGFR-mutated non-small cell lung cancer, showing significant improvement in progression-free survival compared to chemotherapy.

Merck/Daiichi Sankyo Partnered Lung Cancer Candidate Meets Primary Goal In Late-Stage Study

DAIICHI SANKYO S/ADR by Daiichi Sankyo Co., Ltd.

Daiichi Sankyo Co Ltd

AstraZeneca antibody drug conjugate fails to meet overall survival goal in breast cancer

Top quant-rated Japan stocks as BoJ will likely stop rate hikes in 2024 – Jefferies

AstraZeneca's Enhertu application accepted by FDA with priority review

Daiichi Sankyo Company, Limited 2024 Q2 - Results - Earnings Call Presentation

Daiichi Sankyo Company, Limited (DSKYF) Q2 2025 Earnings Call Transcript

AstraZeneca, Daiichi file for FDA accelerated approval of Dato-DXd

AstraZeneca raised to neutral at UBS despite China headwinds

Franklin International Growth Fund Q3 2024 Commentary

AstraZeneca cancer drug Enhertu added for reimbursement in China despite probe

AstraZeneca gets FDA breakthrough therapy status for Dato-DXd

CEVMF

CEVMY

CYBR

DISPF

DSCSY

DSDVF

DSDVY

EVOTF

EXPGF

EXPGY

FRCOY

FUJHY

FUJIY

GMAB

GNMSF

ICGUF

KNBWY

KUBTY

KXSCF

MELI

MUFG

NJDCY

NSANY

PMMAF

PUMSY

RHHBF

RHHBY

RYKKY

SHOP

SKFOF

STBFY

SXYAY

TTDKY

TYIDY

Press Releases

Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig

Alteogen enters into an Exclusive License Agreement to Develop and Commercialize Subcutaneous ENHERTU® Enabled by Alteogen's Hybrozyme™ Technology

GRAIL Announces First Patient Tested With Blood-Based Assay in Global Phase 3 Adjuvant Lung Cancer Study

CGEN

GRAL

TYO:4568

Comments

Daiichi Sankyo Co

Daiichi Sankyo Co (DSNKY) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga